Pharma companies can optimise R&D budgets using advanced technologies

Pharma companies can optimise their R&D budgets to maximise innovation and deliver high-value therapies by using combination of new technologies to enhance innovation, feed the drug-development pipeline and speed to market.

- 

Sophisticated modelling techniques, such as systems biology, can be used to enhance innovation. Model Integrated Approach (PBPK modelling) can be used to predict bioequivalence and can replace some of clinical or bioequivalence studies requirement. Real-world evidence (RWE), new approaches to clinical trials and partnerships, and artificial intelligence (AI) have the potential to transform R&D from drug discovery and development to regulatory approval. Advances in the availability and analysis of real-world data (RWD) have increased the potential for generating robust RWE to support FDA regulatory decisions. Regulatory agencies are accepting the use of RWE in submissions and US FDA has approved several products using RWE.